WallStreetZenWallStreetZen

NASDAQ: PTGX
Protagonist Therapeutics Revenue

OverviewForecastEarningsRevenue
DividendOwnership
Protagonist Therapeutics revenue was $46.02M for the trailing 12 months ending Dec 31, 2025, with N/A growth year over year. Quarterly revenue for the quarter (Q4 2025) ending on Dec 31, 2025 was $7.4M, up 57.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, PTGX annual revenue was $46.0M, with -89.4% growth year-over-year.

PTGX past revenue growth

How has PTGX's revenue growth performed historically?

Company
-89.41%
Industry
465.24%
Market
90.32%
PTGX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
PTGX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
PTGX's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

PTGX revenue history

Current Revenue
$46.0M
Current Earnings
-$130.1M
Current Profit Margin
-282.8%

Be the first to know when PTGX announces revenue.

PTGX Revenue History By Year

PTGX Yearly RevenuePTGX RevenuePTGX ChangePTGX Revenue Growth
2025-12-31$46.02M-$388.42M-89.41%
2024-12-31$434.43M$374.43M+624.06%
2023-12-31$60.00M$33.42M+125.73%
2022-12-31$26.58M-$776.00k-2.84%
2021-12-31$27.36M-$1.27M-4.44%
2020-12-31$28.63M$28.40M+12,293.07%
2019-12-31$231.00k-$30.69M-99.25%
2018-12-31$30.93M$10.86M+54.14%
2017-12-31$20.06MN/AN/A
2016-12-31$0.00N/AN/A
2015-12-31$0.00N/AN/A
2014-12-31$0.00N/AN/A

1 of 1

Protagonist Therapeutics Revenue FAQ

What was PTGX's revenue last quarter?

On Invalid Date, Protagonist Therapeutics (NASDAQ: PTGX) reported Q4 2025 revenue of $7.44 million up 95.64% year over year. In the same quarter last year, Protagonist Therapeutics's revenue was $170.64 million.

What was Protagonist Therapeutics's revenue in 2025?

Protagonist Therapeutics's annual revenue for the twelve months ending Dec 31, 2025 was $46.02 million, a 89.41% decrease year over year.

How much does Protagonist Therapeutics make in a day?

Based on Protagonist Therapeutics annual revenue for the past five years, PTGX makes an average of $325,691.51 per day.

What was Protagonist Therapeutics's annual revenue growth in the past year?

As of Q1 2026, Protagonist Therapeutics's revenue has grown -89.41% year over year. This is 554.65 percentage points lower than the US Biotechnology industry revenue growth rate of 465.24%. Protagonist Therapeutics's revenue in the past year totaled $46.02 million.

How much does Protagonist Therapeutics make in a year?

Protagonist Therapeutics's revenue by year for the past five years is:
  • Protagonist Therapeutics's revenue for the twelve months ending Dec 31, 2025 was $46.02 million, a 89.41% decrease year over year.
  • Protagonist Therapeutics's annual revenue for Dec 31, 2024 was $434.43 million, a 624.06% increase from 2023.
  • Protagonist Therapeutics's annual revenue for 2023 was $60.00 million, a 125.73% increase from 2022.
  • Protagonist Therapeutics's annual revenue for 2022 was $26.58 million, a 2.84% decrease from 2021.
  • Protagonist Therapeutics's annual revenue for 2021 was $27.36 million, a 4.44% decrease from 2020.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.